Targeting the PD-1 Pathway in MSI-Stable Metastatic Colorectal Cancer
نویسندگان
چکیده
Kaijun Huang1 and Jennifer Wu2* 1Department of Medicine, NYU Lutheran Medical Center, Brooklyn, NY, USA 2Department of Medicine, Division of Hematology-Oncology, Laura and Isaac Perlmutter Cancer Center, New York, NY, USA *Corresponding author: Jennifer Wu, Department of Medicine, Division of Hematology-Oncology, Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine 462 First Avenue, New York, NY 10016, Tel: 212-263-6485; E-mail: [email protected]
منابع مشابه
Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.
A recent phase II study of patients with metastatic colorectal carcinoma showed that mismatch repair gene status was predictive of clinical response to PD-1-targeting immune checkpoint blockade. Further examination revealed strong correlation between PD-L1 protein expression and microsatellite instability (MSI) in stage IV colorectal carcinoma, suggesting that the amount of PD-L1 protein expres...
متن کاملResponse to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation.
Recent clinical evidence has demonstrated that microsatellite instability (MSI) or defective mismatch repair (MMR) and high tumor mutational load can predict response to the programmed cell death 1 (PD-1) receptor inhibitor pembrolizumab in metastatic colorectal cancer (mCRC). Mutations in polymerase ε (POLE), a DNA polymerase involved in DNA replication and repair, contribute to an ultramutate...
متن کاملThe microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy.
The microsatellite instable (MSI) subset of colorectal cancer exhibits an active Th1/CTL immune microenvironment, probably due to recognition of a high number of tumor neoantigens. However, the high expression of checkpoint molecules PD-1, PD-L1, CTLA-4, LAG-3, and IDO in MSI colorectal cancer distinguishes MSI from microsatellite stable colorectal cancer and creates an immunosuppressive microe...
متن کاملToward a Molecular Classification of Colorectal Cancer: The Role of BRAF
Different genetic aberrations of BRAF have been reported in various malignancies. BRAF is member of the RAS/RAF/MEK/ERK pathway and constitutive activity of this pathway can lead to increased cellular growth, invasion, and metastasis. The most common activating BRAF mutation in colorectal cancer is the V600E mutation, which is present in 5-15% of all tumors, and up to 80% of tumors with high mi...
متن کاملPseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review
Evading tumor-mediated immunosuppression through antibodies to immune checkpoints has shown clinical benefit in patients with select solid tumors. There is a heterogeneity of responses in patients receiving immunotherapy, including pseudoprogression in which the tumor burden increases initially before decreasing to reach disease control. The characteristics and basis of pseudoprogression, howev...
متن کامل